ZTS
Zoetis Inc.Evidence as of 2026-09-02Overview · Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectiv…
Management team
- Mr. Nick Ashton · Executive VP and President of Global Manufacturing & SupplyFind on LinkedIn
- Ms. Jeannette Ferran Astorga · Executive VP of Corporate Affairs & Communications and Chief Sustainability OfficerFind on LinkedIn
- Dr. Robert J. Polzer Ph.D. · Executive VP and President of Research & DevelopmentFind on LinkedIn
- Mr. Steven Frank · Vice President of Investor RelationsFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.1 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.1 of a possible +2; was -0.1 before debate) · confidence high. Revenues rose from USD 2,262,000,000 in Q1 2026 (fiscal quarter ended 2026-05-01) to USD 2,468,000,000 in Q2 2026 (fiscal quarter ended 2026-07-31), while net income increased from USD 606,000,000 in Q1 2026 to USD 691,000,000 in Q2 2026 and diluted EPS moved from USD 1.42 to USD 1.65 over the same quarters. Reported common shares outstanding declined from 456,295,137 as of 2024-04-26 to 413,223,602 as of 2026-07-31, and long-term noncurrent debt rose from USD 5,220,000,000 as of 2024-12-31 to USD 9,042,000,000 as of 2026-06-30.
Market evidence shows a large multi-year drawdown ( -62.7% three-year max drawdown, -59.9% from the three-year high) with weak recent momentum ( six-month momentum -38.4%, 12-1 momentum -46.5%) and elevated short- and medium-term volatility ( vol_30d_annualized +37.5%, vol_90d_annualized +50.0%). Valuation and capital metrics in the packet include a share price of $ 77.25 (2026-09-01), trailing twelve-month P/E 12.2, market cap $ 31,921,523,254 and enterprise value $ 39,493,523,254; the packet is missing TTM EBITDA and free-cash-flow inputs.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenues increased from USD 2,262,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31) to USD 2,468,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30).
XBRL companyfacts · 0001555280-26-000024Net income rose from USD 606,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31) to USD 691,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30); diluted EPS increased from USD 1.42 in fiscal Q1 2026 to USD 1.65 in fiscal Q2 2026.
XBRL companyfacts · 0001555280-26-000024Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
In the press release furnished on August 6, 2026, the company reported second-quarter 2026 revenue of $2,468 million versus $2,474 million in the comparable 2025 quarter, with foreign exchange contributing +2% and operational changes contributing -2% for the three months ended June 30, 2026.
8-K filed 2026-08-06In the Management's Discussion and Analysis filed on August 6, 2026 (Form 10-Q), the company reported six months ended June 30, 2026 revenue of $4,730 million versus $4,672 million for the six months ended June 30, 2025, a total increase of 1% composed of +2% from foreign exchange and -1% operationally.
10-Q filed 2026-08-06Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
As of 2026-09-01, the 3-year max drawdown is -62.7% and the drawdown from the 3-year high is -59.9%, with the rank_drawdown_3y at the 7th percentile of the 547-stock universe.
Moneyta signal set · 2026-09-01As of 2026-09-01, 6-month momentum is -38.4% (rank_momentum_6m: 2th percentile of 547) and the 12-1 momentum is -46.5% (rank_momentum_12_1: 5th percentile of 547), indicating weak recent price momentum relative to the universe.
Moneyta signal set · 2026-09-01Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
The latest reported 13F aggregate institutional value for the company is "$47.15B", as of the period 2026-03-31.
13F holdings · 1605 filers · as of 2026-03-31Top reported institutional holders in the 13F include BlackRock, Inc. at "$4.21B", VANGUARD CAPITAL MANAGEMENT LLC at "$3.08B", and VANGUARD PORTFOLIO MANAGEMENT LLC at "$2.83B" (as shown in the 13F for the period ended 2026-03-31).
13F holdings · 1605 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple recent regulatory filings reported new or changed institutional stakes in Zoetis during the second quarter, including a new 202,749-share position by Moore Capital Management LP.
News · thelincolnianonline.com · 2026-08-31Several filings also reported reductions or sales of Zoetis shares in the second quarter, for example Benjamin Edwards Inc. reduced its stake by 61.7% and HSBC Holdings PLC trimmed its holding by 10.8%.
News · thelincolnianonline.com · 2026-08-31Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Frank A. D'Amelio executed an open-market purchase of 6,650 shares on 2026-05-13 for "$501k" according to the filing.
Form 4 · DAMELIO FRANK A (Director) · $501k bought · 2026-05-13Paul Bisaro executed an open-market purchase of 2,000 shares on 2026-05-13 for "$152k" according to the filing.
Form 4 · Bisaro Paul (Director) · $152k bought · 2026-05-13Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The reported share price used in this analysis is $77.25 as of 2026-09-01.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month price-to-earnings (P/E) is 12.2 according to the provided metrics.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Company-filed financials show sequential quarter-over-quarter revenue and net income increases in Q2 2026 versus Q1 2026, with diluted EPS rising in the same interval; these figures come from the company’s Form 10-Q/press release and are direct primary sources. Share count has meaningfully declined over the 2024–2026 window per reported common shares outstanding, supporting per-share metric improvement on a sourced basis. Company filings also show substantial operating cash flow on a trailing twelve‑month basis, which—taken together with disclosed revenue and EPS momentum and recent product-specific regulatory news (FDA EUA for Simparica Trio)—constitutes company-specific evidence supporting a favorable operational read. While market-price indicators show large drawdowns and weak momentum, those are market outcomes distinct from the company’s reported operating results; the rise in long-term debt is clearly disclosed in the company filing but is balanced in the evidence set by reported cash and robust operating cash flow. Insider open‑market purchases and recent institutional buys are documented in regulatory filings and news items, providing incremental, directly sourced signals of insider and some institutional interest.
Chair's verdict, claim by claim
Fragility · computed, not argued
diversified0.28
44 surviving claims rest on 25 distinct sources; the heaviest analyst carries 23% of them, and 100% of what the desk raised survived the debate.
The evidence base is moderately broad but not highly robust: 44 surviving claims rely on 25 distinct sources, so multiple points cross-check each other, yet a single analyst or contributor still accounts for nearly a quarter of the surviving claims. The fact that 100% of raised issues survived debate suggests low internal challenge — this increases the chance that overlooked assumptions or common-source biases persist, so treat the read as informative but somewhat fragile.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
21 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.2 to the score
7 documents· 4 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.2 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−1.0 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis−0.2 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
10 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot+0.3 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on ZTS Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.